tert-Butyl ((R)-4-Oxo-4-(((R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)amino)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate

CAS : 2088771-62-2

Ref. TR-B208870

Informations sur le produit

• Nom: tert-Butyl ((R)-4-Oxo-4-(((R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)amino)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate
• Synonymes: Carbamic acid, N-[(1R)-3-[[(1R)-3-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]amino]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (ACI)

Description

Applications tert-Butyl ((R)-4-Oxo-4-(((R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)amino)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate is an intermediate in the synthesis of 3-Amino-4-(2,4,5-trifluorophenyl)butanyl Sitagliptin (A633385), which is an impurity of Sitagliptin (S490990). Sitagliptin is a trizolopyrazine dipeptidyl peptidase IV inhibitor. It has recently been approved for the therapy of type II diabetes.
References Kim, D., et al.: J. Med. Chem., 48, 141 (2005), Ahren, B., et al.: Eur. J. Pharmacol., 521 164 (2005), Bergman, A., et al: Clin. Ther., 28, 55 (2006)

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 722.601
• Formule: C₃₁H₃₁F₉N₆O₄
• Couleur/Forme: Neat
• InChI: InChI=1S/C31H31F9N6O4/c1-30(2,3)50-29(49)42-17(6-15-8-21(34)23(36)12-19(15)32)10-26(47)41-18(7-16-9-22(35)24(37)13-20(16)33)11-27(48)45-4-5-46-25(14-45)43-44-28(46)31(38,39)40/h8-9,12-13,17-18H,4-7,10-11,14H2,1-3H3,(H,41,47)(H,42,49)/t17-,18-/m1/s1
• Code InChI: InChIKey=ZPWWGTPYIACDPL-QZTJIDSGSA-N
• SMILES: CC(C)(C)OC(=O)N[C@@H](CC(=O)N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F)Cc1cc(F)c(F)cc1F